Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. The CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Phone408-716-4600
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$418.79 million
Profitability
Miscellaneous
Employees998
Next Earnings Date10/29/2019 (Confirmed)
OptionableOptionable
Accuray (NASDAQ:ARAY) Frequently Asked Questions
What is Accuray's stock symbol?
Accuray trades on the NASDAQ under the ticker symbol "ARAY."
How were Accuray's earnings last quarter?
Accuray Incorporated (NASDAQ:ARAY) posted its quarterly earnings results on Thursday, August, 15th. The medical equipment provider reported ($0.02) EPS for the quarter, missing analysts' consensus estimates of $0.03 by $0.05. The medical equipment provider had revenue of $117.42 million for the quarter, compared to analyst estimates of $116.09 million. Accuray had a negative return on equity of 26.69% and a negative net margin of 3.92%. During the same period last year, the firm posted ($0.01) EPS. View Accuray's Earnings History.
When is Accuray's next earnings date?
How can I listen to Accuray's earnings call?
Accuray will be holding an earnings conference call on Tuesday, October 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Accuray issued on next quarter's earnings?
Accuray updated its FY 2020 earnings guidance on Thursday, August, 15th. The company provided EPS guidance of for the period. The company issued revenue guidance of $410-420 million, compared to the consensus revenue estimate of $436.86 million.
What price target have analysts set for ARAY?
3 Wall Street analysts have issued 1-year price targets for Accuray's shares. Their forecasts range from $3.90 to $4.00. On average, they expect Accuray's share price to reach $3.95 in the next twelve months. This suggests a possible upside of 47.4% from the stock's current price. View Analyst Price Targets for Accuray.
What is the consensus analysts' recommendation for Accuray?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Accuray in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Accuray.
Has Accuray been receiving favorable news coverage?
Media stories about ARAY stock have been trending somewhat negative this week, according to InfoTrie Sentiment. The research firm identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Accuray earned a coverage optimism score of -1.2 on InfoTrie's scale. They also gave news coverage about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View News Stories for Accuray.
Are investors shorting Accuray?
Accuray saw a drop in short interest in the month of September. As of September 30th, there was short interest totalling 1,920,000 shares, a drop of 21.3% from the August 30th total of 2,440,000 shares. Based on an average daily trading volume, of 588,200 shares, the days-to-cover ratio is presently 3.3 days. Currently, 2.2% of the company's shares are short sold. View Accuray's Current Options Chain.
Who are some of Accuray's key competitors?
Some companies that are related to Accuray include Luminex (LMNX), Cryolife (CRY), Shockwave Medical (SWAV), Tactile Systems Technology (TCMD), Anika Therapeutics (ANIK), Cerus (CERS), LeMaitre Vascular (LMAT), SurModics (SRDX), Axonics Modulation Technologies (AXNX), MiMedx Group (MDXG), Antares Pharma (ATRS), AngioDynamics (ANGO), Intersect ENT (XENT), Orthopediatrics (KIDS) and OraSure Technologies (OSUR).
What other stocks do shareholders of Accuray own?
Who are Accuray's key executives?
Accuray's management team includes the folowing people:
- Mr. Joshua H. Levine, Pres, CEO & Director (Age 61)
- Mr. Andrew Kirkpatrick, Sr. VP & COO (Age 56)
- Mr. Lionel Hadjadjeba, Sr. VP & Chief Customer Experience Officer (Age 60)
- Mr. Shigeyuki Hamamatsu, Sr. VP & CFO (Age 46)
- Mr. Patrick R. Spine, Sr. VP & Chief Admin. Officer
How do I buy shares of Accuray?
Shares of ARAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Accuray's stock price today?
One share of ARAY stock can currently be purchased for approximately $2.68.
How big of a company is Accuray?
Accuray has a market capitalization of $237.93 million and generates $418.79 million in revenue each year. The medical equipment provider earns $-16,430,000.00 in net income (profit) each year or ($0.15) on an earnings per share basis. Accuray employs 998 workers across the globe.View Additional Information About Accuray.
What is Accuray's official website?
How can I contact Accuray?
Accuray's mailing address is 1310 CHESAPEAKE TERRACE, SUNNYVALE CA, 94089. The medical equipment provider can be reached via phone at 408-716-4600 or via email at [email protected]
MarketBeat Community Rating for Accuray (NASDAQ ARAY)
MarketBeat's community ratings are surveys of what our community members think about Accuray and other stocks. Vote "Outperform" if you believe ARAY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARAY will underperform the S&P 500 over the long term. You may vote once every thirty days.
